[go: up one dir, main page]

AR071811A1 - Derivados de diazol como activadores de glucoquinasa - Google Patents

Derivados de diazol como activadores de glucoquinasa

Info

Publication number
AR071811A1
AR071811A1 ARP090101763A AR071811A1 AR 071811 A1 AR071811 A1 AR 071811A1 AR P090101763 A ARP090101763 A AR P090101763A AR 071811 A1 AR071811 A1 AR 071811A1
Authority
AR
Argentina
Prior art keywords
alkyl
heterobicycloaryl
heterocycloalkyl
bicycloaryl
cycloalkyl
Prior art date
Application number
Other languages
English (en)
Inventor
Zacharia Cheruvallath
Stephen L Gwaltney
Mark Sabat
Jeffrey A Stafford
Mingnam Tang
Haxia Wang
Andrew J Jennings
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41076813&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR071811(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AR071811A1 publication Critical patent/AR071811A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Adem s se proveen composiciones farmaceuticas, kits y art¡culos de fabricacion que comprenden estos compuestos; metodos e intermediarios utiles para producir los compuestos; y metodos para utilizar dichos compuestos. Reivindicacion 1: Un compuesto que tiene la formula: o un polimorfo, solvato, ester, tautomero, enantiomero, sal o prodroga del mismo aceptable para uso farmaceutico, donde R1 se selecciona del grupo integrado por heterocicloalquilo C3-12, heterobicicicloalquilo C3-12, heteroarilo, y heterobicicloarilo C4-12, cada uno sustituido o no sustituido; R2 se selecciona del grupo integrado por hidrogeno y un sustituyente que puede convertirse a hidrogeno in vivo; R3 se selecciona del grupo integrado por hidrogeno, carbonilo, sulfonilo, sulfinilo, alquilo C1-10, haloalquilo C1-10, carbonilalquilo C1-3, tiocarbonilalquilo C1-3, sulfonilalquilo C1-3, sulfinilalquilo C1-3, aminoalquilo C1-10, iminoalquilo C1-3, cicloalquilo C3-12-alquilo C1-5, heterocicloalquilo C3-12-alquilo C1-5, arilalquilo C1-10, heteroarilalquilo C1-5, bicicloarilo C9-12-alquilo C1-5, heterobicicloarilo C8-12-alquilo C1-5, cicloalquilo C3-12, heterocicloalquilo C3-12, bicicloalquilo C9-12, heterobicicicloalquilo C3-12, arilo, heteroarilo, bicicloarilo C9-12 y heterobicicloarilo C4-12, cada uno sustituido o no sustituido, o R3 es -L-R18; R4 se selecciona del grupo integrado por hidrogeno, carbonilo, sulfonilo, sulfinilo, alquilo C1-10, haloalquilo C1-10, carbonilalquilo C1-3, tiocarbonilalquilo C1-3, sulfonilalquilo C1-3, sulfinilalquilo C1-3, aminoalquilo C1-10, iminoalquilo C1-3, cicloalquilo C3-12-alquilo C1-5, heterocicloalquilo C3-12-alquilo C1-5, arilalquilo C1-10, heteroarilalquilo C1-5, bicicloarilo C9-12-alquilo C1-5, heterobicicloarilo C8-12-alquilo C1-5, cicloalquilo C3-12, heterocicloalquilo C3-12, bicicloalquilo C9-12, heterobicicicloalquilo C3-12, arilo, heteroarilo, bicicloarilo C9-12 y heterobicicloarilo C4-12, cada uno sustituido o no sustituido, o R3 y R4 se toman juntos para formar un anillo sustituido o no sustituido; R5 se selecciona del grupo integrado por hidrogeno, halo, nitro, ciano, tio, oxi, hidroxi, carboniloxi, alcoxi C1-10, ariloxi C4-12, heteroariloxi C1-10, carbonilo, oxicarbonilo, amido, amino, alquilamino C1-10, sulfonamido, imino, sulfonilo, sulfinilo, alquilo C1-10, haloalquilo C1-10, hidroxialquilo C1-10, carbonilalquilo C1-10, tiocarbonilalquilo C1-10, sulfonilalquilo C1-10, sulfinilalquilo C1-10, azaalquilo C1-10, oxaalquilo C1-10, oxoalquilo C1-10, iminoalquilo C1-10, cicloalquilo C3-12-alquilo C1-5, heterocicloalquilo C3-12-alquilo C1-10, arilalquilo C1-10, heteroarilo C1-10-alquilo C1-5, bicicloarilo C9-12-alquilo C1-5, heterobicicloarilo C8-12-alquilo C1-5, heteroalquilo C1-10, cicloalquilo C3-12, heterocicloalquilo C3-12, bicicloalquilo C9-12, heterobicicicloalquilo C3-12, arilo C4-12, heteroarilo C1-10, bicicloarilo C9-12 y heterobicicloarilo C4-12, cada uno sustituido o no sustituido; R6 se selecciona del grupo integrado por hidrogeno, halo, nitro, ciano, tio, oxi, hidroxi, carboniloxi, alcoxi C1-10, ariloxi C4-12, heteroariloxi C1-10, carbonilo, oxicarbonilo, amido, amino, alquilamino C1-10, sulfonamido, imino, sulfonilo, sulfinilo, alquilo C1-10, haloalquilo C1-10, hidroxialquilo C1-10, carbonilalquilo C1-10, tiocarbonilalquilo C1-10, sulfonilalquilo C1-10, sulfinilalquilo C1-10, azaalquilo C1-10, oxaalquilo C1-10, oxoalquilo C1-10, iminoalquilo C1-10, cicloalquilo C3-12-alquilo C1-5, heterocicloalquilo C3-12-alquilo C1-10, Arilalquilo C1-10, heteroarilo C1-10-alquilo C1-5, bicicloarilo C9-12-alquilo C1-5, heterobicicloarilo C8-12-alquilo C1-5, heteroalquilo C1-10, cicloalquilo C3-12, bicicloalquilo C9-12, heterobicicicloalquilo C3-12, arilo C4-12, heteroarilo C1-10, bicicloarilo C9-12 y heterobicicloarilo C4-12, cada uno sustituido o no sustituido, o R6 es -L1-R22 R7 se selecciona del grupo integrado por hidrogeno, halo, nitro, ciano, tio, oxi, hidroxi, carboniloxi, alcoxi C1-10, ariloxi C4-12, heteroariloxi C1-10, carbonilo, oxicarbonilo, amido, amino, alquilamino C1-10, sulfonamido, imino, sulfonilo, sulfinilo, alquilo C1-10, haloalquilo C1-10, hidroxialquilo C1-10, carbonilalquilo C1-10, tiocarbonilalquilo C1-10, sulfonilalquilo C1-10, sulfinilalquilo C1-10, azaalquilo C1-10, oxaalquilo C1-10, oxoalquilo C1-10, iminoalquilo C1-10, cicloalquilo C3-12-alquilo C1-5, heterocicloalquilo C3-12-alquilo C1-10, arilalquilo C1-10, heteroarilo C1-10-alquilo C1-5, bicicloarilo C9-12-alquilo C1-5, heterobicicloarilo C8-12-alquilo C1-5, heteroalquilo C1-10, cicloalquilo C3-12, heterocicloalquilo C3-12, bicicloalquilo C9-12, heterobicicicloalquilo C3-12, arilo C4-12, heteroarilo C1-10, bicicloarilo C9-12 y heterobicicloarilo C4-12, cada uno sustituido o no sustituido, o R7 es -L1-R22 o cualquiera dos R5, R6 y R7 se toman juntos para formar un anillo sustituido o no sustituido; L es un conector que suministra 0, 1, 2, 3, 4, 5 o 6 separaciones de  tomo entre el C y R18 al cual L est  unido, donde los  tomos del conector que suministran la separacion se seleccionan del grupo integrado por carbono, ox¡geno, nitrogeno, y azufre; L1 est  ausente o un conector que suministra 1, 2, 3, 4, 5 o 6 separaciones de  tomo entre R22 y el anillo al cual L1 est  unido, donde los  tomos del conector que suministran la separacion se seleccionan del grupo integrado por carbono, ox¡geno, nitrogeno, y azufre; R18 se selecciona del grupo integrado por hidrogeno, halo, nitro, ciano, tio, oxi, hidroxi, carboniloxi, alcoxi C1-10, ariloxi C4-12, heteroariloxi C1-10, carbonilo, oxicarbonilo, amido, amino, alquilamino C1-10, sulfonamido, imino, sulfonilo, sulfinilo, alquilo C1-10, haloalquilo C1-10, hidroxialquilo C1-10, carbonilalquilo C1-10, tiocarbonilalquilo C1-10, sulfonilalquilo C1-10, sulfinilalquilo C1-10, azaalquilo C1-10, oxaalquilo C1-10, oxoalquilo C1-10, iminoalquilo C1-10, cicloalquilo C3-12-alquilo C1-5, heterocicloalquilo C3-12-alquilo C1-10, arilalquilo C1-10, heteroarilo C1-10-alquilo C1-5, bicicloarilo C9-12-alquilo C1-5, heterobicicloarilo C8-12-alquilo C1-5, heteroalquilo C1-10, cicloalquilo C3-12, heterocicloalquilo C3-12, bicicloalquilo C9-12, heterobicicicloalquilo C3-12, arilo C4-12, heteroarilo C1-10, bicicloarilo C9-12 y heterobicicloarilo C4-12, cada uno sustituido o no sustituido; R22 se selecciona del grupo integrado por hidrogeno, halo, nitro, ciano, t¡o, oxi, hidroxi, carboniloxi, alcoxi C1-10, ariloxi C4-12, heteroariloxi C1-10, carbonilo, oxicarbonilo, amido, amino, alquilamino C1-10, sulfonamido, imino, sulfonilo, sulfinilo, alquilo C1-10, haloalquilo C1-10, hidroxialquilo C1-10, carbonilalquilo C1-10, tiocarbonilalquilo C1-10, sulfonilalquilo C1-10, sulfinilalquilo C1-10, azaalquilo C1-10, oxaalquilo C1-10, oxoalquilo C1-10, iminoalquilo C1-10, cicloalquilo C3-12-alquilo C1-5, heterocicloalquilo C3-12-alquilo C1-10, arilalquilo C1-10, heteroarilo C1-10-alquilo C1-5, bicicloarilo C9-12-alquilo C1-5, heterobicicloarilo C8-12-alquilo C1-5, heteroalquilo C1-10, cicloalquilo C3-12, heterocicloalquilo C3-12, bicicloalquilo C9-12, heterobicicicloalquilo C3-12, arilo C4-12, heteroarilo C1-10, bicicloarilo C9-12 y heterobicicloarilo C4-12, cada uno sustituido o no sustituido, o R22 es -NR27R28 y R27 y R28 se seleccionan cada uno de ellos independientemente del grupo integrado por hidrogeno, hidroxi, alcoxi, ariloxi, heteroariloxi, carbonilo, amino, alquilamino C1-10, sulfonamido, imino, sulfonilo, sulfinilo, alquilo C1-10, haloalquilo C1-10, carbonilalquilo C1-3, tiocarbonilalquilo C1-3, sulfonilalquilo C1-3, sulfinilalquilo C1-3, aminoalquilo C1-10, iminoalquilo C1-3, cicloalquilo C3-12-alquilo C1-5, heterocicloalquilo C3-12-alquilo C1-5, arilalquilo C1-10, heteroarilalquilo C1-5, bicicloarilo C9-12-alquilo C1-5, heterobicicloarilo C8-12-alquilo C1-5, cicloalquilo C3-12, heterocicloalquilo C3-12, bicicloalquilo C9-12, heterobicicicloalquilo C3-12, arilo, heteroarilo, bicicloarilo C9-12 y heterobicicloarilo C4-12, cada uno sustituido o no sustituido, o R27 y R28 se toman juntos para formar un anillo sustituido o no sustituido, con la condicion que (a) R1 no sea 5-(3-acetamidociclobutil)-1H-pirazol-3-ilo cuando R5 y R6, junto con el anillo al cual ellos est n unidos, formen un indazol-1-ilo no sustituido; y (b) R1 no sea 5-(2-clorobencil)tiazol-2-ilo cuando R3 sea fenilo y R2, R4, R5, R6 y R7 sean todos hidrogeno.
ARP090101763 2008-05-16 2009-05-15 Derivados de diazol como activadores de glucoquinasa AR071811A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5405208P 2008-05-16 2008-05-16
US10837008P 2008-10-24 2008-10-24

Publications (1)

Publication Number Publication Date
AR071811A1 true AR071811A1 (es) 2010-07-14

Family

ID=41076813

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101763 AR071811A1 (es) 2008-05-16 2009-05-15 Derivados de diazol como activadores de glucoquinasa

Country Status (27)

Country Link
US (4) US8563730B2 (es)
EP (1) EP2294053B1 (es)
JP (1) JP5513492B2 (es)
KR (1) KR20110018366A (es)
CN (1) CN102105451B (es)
AR (1) AR071811A1 (es)
AU (1) AU2009246167B2 (es)
BR (1) BRPI0912802A2 (es)
CA (1) CA2724116A1 (es)
CL (1) CL2009001203A1 (es)
CO (1) CO6321274A2 (es)
CR (1) CR11827A (es)
DO (1) DOP2010000351A (es)
EA (1) EA018988B1 (es)
EC (1) ECSP10010688A (es)
GE (1) GEP20135783B (es)
IL (1) IL209062A (es)
MA (1) MA32391B1 (es)
MX (1) MX2010012298A (es)
MY (1) MY152749A (es)
NZ (1) NZ589084A (es)
PE (2) PE20141375A1 (es)
SG (1) SG190625A1 (es)
TW (1) TWI445707B (es)
UY (1) UY31830A (es)
WO (1) WO2009140624A2 (es)
ZA (1) ZA201007975B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8642597B2 (en) * 2007-08-27 2014-02-04 Basf Se Pyrazole compounds for controlling invertebrate pests
AU2009210641A1 (en) * 2008-02-05 2009-08-13 Merck Sharp & Dohme Corp. Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-IV inhibitor
PE20141375A1 (es) 2008-05-16 2014-10-23 Takeda San Diego Inc Activadores de glucoquinasa
ES2423289T3 (es) 2008-08-27 2013-09-19 Takeda Pharmaceutical Company Limited Compuestos de pirrol
CA2735184C (en) * 2008-09-11 2013-05-28 Pfizer Inc. Heteroaryls amide derivatives and their use as glucokinase activators
EA020661B1 (ru) 2008-09-24 2014-12-30 Басф Се Пиразольные соединения для борьбы с беспозвоночными вредителями
WO2011003793A1 (en) 2009-07-06 2011-01-13 Basf Se Pyridazine compounds for controlling invertebrate pests
WO2011003796A1 (en) 2009-07-06 2011-01-13 Basf Se Pyridazine compounds for controlling invertebrate pests
CN102469785A (zh) 2009-07-24 2012-05-23 巴斯夫欧洲公司 防治无脊椎动物害虫的吡啶衍生物
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CN105176930B (zh) 2010-03-31 2021-05-04 斯克里普斯研究所 重编程细胞
NZ603614A (en) 2010-05-26 2014-10-31 Transtech Pharma Llc Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
EP2627654A1 (en) 2010-10-13 2013-08-21 Takeda California, Inc. Method of making azaindazole derivatives
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EA201492109A1 (ru) 2012-05-17 2015-07-30 ТРАНСТЕК ФАРМА ЭлЭлСи Композиции активатора глюкокиназы для лечения сахарного диабета
MX2015011109A (es) * 2013-03-04 2015-11-16 Vtv Therapeutics Llc Composiciones estables de activador de glucoquinasa.
EP2878339A1 (en) 2013-12-02 2015-06-03 Siena Biotech S.p.A. SIP3 antagonists
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
EA201892486A1 (ru) * 2014-12-19 2019-07-31 Арагон Фармасьютикалз, Инк. Способ получения соединения диарилтиогидантоина
CN105092770B (zh) * 2015-01-12 2017-03-29 上海中医药大学 一种筛选二肽基肽酶四抑制剂的方法
EP3307706B1 (en) 2015-06-15 2019-07-24 Bayer CropScience AG Halogen-substituted phenoxyphenylamidines and the use thereof as fungicides
WO2016202742A1 (en) 2015-06-15 2016-12-22 Bayer Cropscience Aktiengesellschaft Halogen-substituted phenoxyphenylamidines and the use thereof as fungicides
WO2018109002A1 (en) 2016-12-14 2018-06-21 Bayer Cropscience Aktiengesellschaft Active compound combinations
EP3335559A1 (en) 2016-12-14 2018-06-20 Bayer CropScience Aktiengesellschaft Active compound combinations
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
CN110548147B (zh) * 2018-05-31 2022-01-14 华领医药技术（上海）有限公司 含有葡萄糖激酶激活剂和dpp-iv抑制剂的药物组合及其制备方法和用途
CN112040945A (zh) 2018-06-12 2020-12-04 Vtv治疗有限责任公司 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
AU2021289309A1 (en) 2020-06-08 2023-01-19 Vtv Therapeutics Llc Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE910278A1 (en) 1990-02-16 1991-08-28 Ici Plc Heterocyclic compounds
US5612360A (en) 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
GB9315846D0 (en) 1993-07-30 1993-09-15 Isis Innovation Tumour inhibitors
US5795726A (en) 1996-11-12 1998-08-18 Millennium Pharmaceuticals, Inc. Methods for identifying compounds useful in treating type II diabetes
GB9806692D0 (en) 1998-03-27 1998-05-27 Pharmacia & Upjohn Spa Benzoheterocyclic distamycin derivatives, process for preparing them and their use as antitumour agents
TR200102805T2 (tr) 1999-03-29 2002-04-22 F.Hoffmann-La Roche Ag Glikokinaz aktivatörleri
US20030013633A1 (en) 1999-06-07 2003-01-16 Rima Kaddurah-Daouk Use of molecules that modulate an energy related associated state
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
CN1911221A (zh) 1999-12-23 2007-02-14 诺瓦提斯公司 降血糖剂用于治疗葡萄糖代谢障碍
AU2001252270B2 (en) 2000-05-03 2005-12-15 F. Hoffmann-La Roche Ag Hydantoin-containing glucokinase activators
EP1283830B1 (en) 2000-05-08 2008-06-18 F. Hoffmann-La Roche Ag Para-amine substituted phenylamide glucokinase activators
JP4138478B2 (ja) 2000-07-20 2008-08-27 エフ．ホフマン−ラ ロシュ アーゲー アルファ−アシル及びアルファ−ヘテロ原子置換ベンゼンアセトアミドのグルコキナーゼアクチベーター
US6433188B1 (en) 2000-12-06 2002-08-13 Wendy Lea Corbett Fused heteroaromatic glucokinase activators
US6482951B2 (en) 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
AU2002352148A1 (en) 2001-06-29 2003-03-03 Abbott Gmnh & Co. Kg Bis-aryl thiazole derivatives
AU2002349299A1 (en) 2001-12-03 2003-06-17 Novo Nordisk A/S Use of a glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes
US20030171411A1 (en) 2001-12-21 2003-09-11 Kodra Janos Tibor Amide derivatives as therapeutic agents
WO2003080585A1 (en) 2002-03-26 2003-10-02 Banyu Pharmaceutical Co., Ltd. Novel aminobenzamide derivative
WO2004026226A2 (en) 2002-05-10 2004-04-01 Cytokinetics, Inc. Compounds, compositions and methods
WO2004002481A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
GB0216097D0 (en) 2002-07-11 2002-08-21 Univ London Treatment of proliferative disorders
AU2003275029A1 (en) 2002-09-27 2004-04-19 Brigham And Women's Hospital, Inc. Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues
NZ539013A (en) 2002-10-03 2007-05-31 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
DE60316709T2 (de) 2002-10-03 2008-07-17 F. Hoffmann-La Roche Ag Indole-3-carbonsaüreamide als glucokinase (gk) aktivatoren
EP1556088A2 (en) 2002-10-29 2005-07-27 Engene, Inc. Compositions for cancer treatment
JP4716734B2 (ja) 2003-01-06 2011-07-06 イーライ リリー アンド カンパニー グルコキナーゼ活性化物質としての置換されたアリールシクロプロピルアセトアミド
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
WO2004072066A1 (en) 2003-02-11 2004-08-26 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
US7179613B2 (en) 2003-05-05 2007-02-20 Vanderbilt University Methods of screening for a candidate modulator of glucokinase
GB0325402D0 (en) * 2003-10-31 2003-12-03 Astrazeneca Ab Compounds
EP1532980A1 (en) 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
WO2005052132A2 (en) 2003-11-24 2005-06-09 Exelixis, Inc Mbms as modifiers of branching morphogenesis and methods of use
GB0328178D0 (en) * 2003-12-05 2004-01-07 Astrazeneca Ab Compounds
RU2412192C2 (ru) 2004-04-02 2011-02-20 Новартис Аг Сульфонамидтиазолпиридиновые производные как активаторы глюкокиназы, пригодные для лечения диабета типа 2
US20080242869A1 (en) 2004-04-21 2008-10-02 Matthew Fyfe Tri(Cyclo) Substituted Amide Compounds
ES2590259T3 (es) 2004-06-17 2016-11-21 Wisconsin Alumni Research Foundation Compuestos y procedimientos para el tratamiento de convulsiones y trastornos paroxísticos
US20080026987A1 (en) 2004-06-17 2008-01-31 Novo Nordisk A/S Use of Liver-Selective Glucokinase Activators
WO2006016194A1 (en) 2004-08-12 2006-02-16 Prosidion Limited Substituted phenylacetamides and their use as glucokinase activators
GB0418058D0 (en) 2004-08-12 2004-09-15 Prosidion Ltd Fluorination process
EP1789107B1 (en) 2004-08-30 2009-05-27 Interstitial Therapeutics Medical stent provided with inhibitors of atp synthesis
CN101111266A (zh) 2005-01-31 2008-01-23 味之素株式会社 含有降血糖药的用于改善或治疗糖耐量异常、临界性糖尿病、胰岛素抵抗性和高胰岛素血症的药物组合物
WO2007001928A2 (en) 2005-06-22 2007-01-04 Merck & Co., Inc. Targets for inhibiting hcv replication
US7565029B2 (en) * 2005-07-08 2009-07-21 Seiko Epson Corporation Method for determining camera position from two-dimensional images that form a panorama
US7514439B2 (en) 2005-07-11 2009-04-07 Mitsubishi Tanabe Pharma Corporation Oxime derivative and preparations thereof
AU2006285834A1 (en) 2005-08-31 2007-03-08 Astellas Pharma Inc. Thiazole derivative
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
WO2007051846A1 (en) * 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides
US20080293741A1 (en) 2005-11-03 2008-11-27 Matthew Colin Thor Fyfe Tricyclo Substituted Amides as Glucokinase Modulators
JP2009515997A (ja) 2005-11-18 2009-04-16 タケダ サン ディエゴ インコーポレイテッド グルコキナーゼ活性剤
US20070244169A1 (en) 2005-12-20 2007-10-18 Jun Feng Glucokinase activators
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
WO2007115968A2 (en) 2006-04-12 2007-10-18 F. Hoffmann-La Roche Ag Process for the preparation of a glucokinase activator
US7842713B2 (en) 2006-04-20 2010-11-30 Pfizer Inc Fused phenyl amido heterocyclic compounds
WO2007122482A1 (en) 2006-04-20 2007-11-01 Pfizer Products Inc. Fused phenyl amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases
EP2049518B1 (en) * 2006-05-31 2011-08-31 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents.
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
WO2008079787A2 (en) 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
JP2010515701A (ja) 2007-01-09 2010-05-13 ノボ・ノルデイスク・エー／エス ウレアグルコキナーゼアクチベーター
WO2008116107A2 (en) 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
US8357637B2 (en) 2007-05-29 2013-01-22 Cornell University Molecules involved in regulation of osteoblast activity and osteoclast activity, and methods of use thereof
WO2009022179A2 (en) 2007-08-14 2009-02-19 Astrazeneca Ab Glucokinase activators in the treatment of osteoarthritis
PE20141375A1 (es) 2008-05-16 2014-10-23 Takeda San Diego Inc Activadores de glucoquinasa
EP2547667A1 (en) 2010-03-18 2013-01-23 Takeda California, Inc. Process for the production of 2-amino-5-fluorothiazole
EP2627654A1 (en) 2010-10-13 2013-08-21 Takeda California, Inc. Method of making azaindazole derivatives

Also Published As

Publication number Publication date
EP2294053A2 (en) 2011-03-16
AU2009246167A1 (en) 2009-11-19
PE20091901A1 (es) 2010-01-06
US20090286800A1 (en) 2009-11-19
CR11827A (es) 2011-03-09
US8563730B2 (en) 2013-10-22
EP2294053B1 (en) 2016-01-06
PE20141375A1 (es) 2014-10-23
JP5513492B2 (ja) 2014-06-04
DOP2010000351A (es) 2011-02-15
SG190625A1 (en) 2013-06-28
US20120225887A1 (en) 2012-09-06
AU2009246167A2 (en) 2010-12-16
CO6321274A2 (es) 2011-09-20
US20140045859A1 (en) 2014-02-13
WO2009140624A2 (en) 2009-11-19
IL209062A (en) 2015-08-31
WO2009140624A3 (en) 2010-05-27
CN102105451A (zh) 2011-06-22
ECSP10010688A (es) 2011-04-29
CN102105451B (zh) 2013-11-13
MX2010012298A (es) 2011-03-15
CA2724116A1 (en) 2009-11-19
UY31830A (es) 2010-01-05
EA201071320A1 (ru) 2011-06-30
US20160009735A1 (en) 2016-01-14
IL209062A0 (en) 2011-01-31
EA018988B1 (ru) 2013-12-30
MA32391B1 (fr) 2011-06-01
NZ589084A (en) 2012-06-29
MY152749A (en) 2014-11-28
GEP20135783B (en) 2013-03-11
JP2011520915A (ja) 2011-07-21
ZA201007975B (en) 2012-02-29
TWI445707B (zh) 2014-07-21
AU2009246167B2 (en) 2013-08-22
US9139598B2 (en) 2015-09-22
BRPI0912802A2 (pt) 2015-10-13
CL2009001203A1 (es) 2009-10-23
KR20110018366A (ko) 2011-02-23
TW200948809A (en) 2009-12-01

Similar Documents

Publication Publication Date Title
AR071811A1 (es) Derivados de diazol como activadores de glucoquinasa
AR071729A1 (es) Inhibidores de quinasas simil polo (plk)
CO6230984A2 (es) Inhibidores de cinasa mapk/erk
AR071452A1 (es) Inhibidores de hsp90
AR063232A1 (es) Pirido (2,3) indoles como inhibidores de quinasas.composiciones farmaceuticas.
AR072936A1 (es) Derivados piridazin y pirimidin condensados con heterociclos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos como agentes anticancer.
CO5700780A2 (es) Derivados de quinolina como inhibidores, selectivos, de de fosfodiesterasa pde 4b
AR061847A1 (es) Derivados de pirimidina 2- amino -5- sustituida. como inhibidores de quinasas. composiciones farmaceuticas.
AR048055A1 (es) Derivados de pirimidina como inhibidores de dipeptidil peptidasa
ES2620531T3 (es) Inhibidores de la fosfodiesterasa tipo 10A
AR056208A1 (es) Compuesto hidrazida y su uso pesticida
PE20130155A1 (es) Derivados de ariletinilo
CO5690642A2 (es) Compuestos de pirazolo[3,4-b]piridina, y su uso como inhibi- dores de fosfodiesterasa
AR044519A1 (es) Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
ES2439255T3 (es) Imidazoheterociclos sustituidos
AR061369A1 (es) Derivados de pirimidina y composiciones farmaceuticas que los comprenden
AR063311A1 (es) Compuestos organicos
AR061058A1 (es) Derivados de piridopirimidininona. procesos de obtencion y composiciones farmaceuticas
AR068376A1 (es) Amidas heterociclicas utiles para inhibir la via hedgehog.
CO6140060A2 (es) Derivados de aminocicloalquil 1,2,4-triazol como moduladores de mglur5
CO6260132A2 (es) Derivados de oxadiazol como inhibidores de dgat
TW200732329A (en) Aryl-isoxazolo-4-yl-oxadiazole derivatives
AR051156A1 (es) Compuestos a base de bicicloheteroarilaminas como ligandos de los canales ionicos,usos de los mismos y composiciones farmaceuticas que los contienen
AR068115A1 (es) Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida
AR046276A1 (es) Derivados de amida como ligandos de canales ionicos y composiciones farmaceuticas y metodos que los utilizan.

Legal Events

Date Code Title Description
FB Suspension of granting procedure